China Biologic Products, Inc. (NASDAQ:CBPO) traded down NaN on Friday . The company traded as low as $82.29 and last traded at $0.00. 1,487,200 shares traded hands during mid-day trading, an increase of Infinity from the average session volume of 0 shares.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered China Biologic Products from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. BidaskClub lowered China Biologic Products from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. China Biologic Products currently has a consensus rating of “Hold” and an average price target of $137.50.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.26 earnings per share.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. bought a new stake in China Biologic Products in the first quarter worth about $156,000. Nomura Holdings Inc. bought a new stake in China Biologic Products in the first quarter worth about $463,000. Jennison Associates LLC lifted its stake in China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after purchasing an additional 44 shares during the last quarter. AHL Partners LLP bought a new stake in China Biologic Products in the second quarter worth about $842,000. Finally, First Trust Advisors LP lifted its stake in China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after purchasing an additional 3,053 shares during the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2017/10/13/china-biologic-products-inc-cbpo-shares-down-nan.html.

About China Biologic Products

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.